← SynDRA
S-55746
SynDRA canonical compound SYN1795921 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | BCL2 |
|---|
| Mechanism of action | bcl inhibitor |
|---|
| Indication | chronic lymphocytic leukemia (cll) |
|---|
| Disease area | hematologic malignancy |
|---|
Cross-references
Synonyms
- s55746
- BCL-201
- BCL201
- W93257I68I
- S-055746
- Servier-1
- RefChem:180613
- BCL-2 INHIBITOR BCL201
- UNII-W93257I68I
- S55746 (BLC201)
- F3Q
- BCL201 diHCl
- BCL-201 diHCl
- Servier 1 dihydrochloride
- BCL-201 dihydrochloride
- orb1309133
- SCHEMBL16411762
- SCHEMBL29371067
- US9120791, Example 1
- US9120791, Example 38
- BDBM177786
- C43H42N4O6
- GLXC-20010
- EX-A4695
- S 55746 [WHO-DD]
- MFCD31715456
- NSC820918
- s8759
- AKOS040737352
- NSC-820918
- T12824L
- DA-67352
- MS-31199
- HY-117288
- CS-0065115
- G16452
- S55746 (S 055746,BCL201)
- N-(4-hydroxyphenyl)-3-[6-[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydro-1H-isoquinoline-2-carbonyl]-1,3-benzodioxol-5-yl]-N-phenyl-5,6,7,8-tetrahydroindolizine-1-carboxamide
Look up S-55746 in the interactive SynDRA portal →